-1 0 0 0 0 0 1 EV1 vs EV7 (opposite)
...
For the high-level analysis we would like to see if there are any differences in the stimulus activation depending on the group the participant belongs to:
* EVs: Please find attached the EVs matrix used for the high-level
analysis, where each EV corresponds to a single group (i.e. EV1 is
HighDrug, EV2 is LowDrug etc).
* Contrasts & F-Test:
HD LD HP LP
C1 4 Groups Mean 1 1 1 1
C2 Drug Mean 1 1 0 0
C3 Placebo Mean 0 0 1 1
C4 High N Mean 1 0 1 0
C5 Low N Mean 0 1 0 1
C6 High N Drug Mean 1 0 0 0
C7 Low N Drug Mean 0 1 0 1
C8 High N Plac. Mean 0 0 1 0
C9 Low N Plac. Mean 0 0 0 1
C10 Main effect drug 1 1 -1 -1
C11 Main effect drug -1 -1 1 1 (opposite)
C12 Main effect of N 1 -1 1 -1
C13 Main effect of N -1 1 -1 1 (opposite)
C14 Main effect of N in drug 1 -1 0 0
C15 Main effect of N in drug -1 1 0 0 (opposite)
C16 Main effect of N in Plac 0 0 1 -1
C17 Main effect of N in Plac 0 0 -1 1 (opposite)
C18 Main effect of drug HN 1 0 -1 0
C19 Main effect of drug HN -1 0 1 0 (opposite)
C20 Main effect of drug LN 0 1 0 -1
C21 Main effect of drug LN 0 -1 0 1 (opposite)
HD: High N + Drug
LD: Low N + Drug
HP: High N + Placebo
LP: Low N + Pacebo
Does this design make sense, or is it necessary to model the effects of
neuroticism and drug group in separate FEATs? And is it possible to
examine an interaction effect between drug group and neuroticism using
this design? Any kind of help would be very
appreciated.
Thank you in advance.
Maria Serra-Blasco
Department of Psychiatry
Warneford Hospital
Oxford
OX3 7JX